Comparison of the antitumor effects of a synthetic biopolymer and standard adjuvants.

The synthetic biopolymer NED 137 is capable of stimulating an immune response to tumor antigen. This article compares the efficacy of NED 137 to bacille Calmette-Guerin, Corynebacterium parvum, pyran, levamisole, and Freund's complete adjuvant in a rat tumor model where adjuvant treatment is administered after excision of subcutaneous tumor implants. A single intraperitoneal injection of NED 137 at 30 mg/kg body weight prolonged survival beyond 60 days with no evidence of recurrent or metastatic disease, whereas with the other adjuvants, animals survived a mean of 30 to 40 days with 100% local recurrence and a 60% to 90% incidence of pulmonary metastases. Use of NED 137 resulted in a greater lysis of tumor cells compared to other adjuvants when assessed in an in vivo 51Cr release assay. A phase I clinical study of high-risk gastrointestinal cancer patients treated with NED 137 is reported at a median survival time of 23 weeks (103 patients). This group is compared to a historical control group from the same institution. No NED 137-related toxicity has been noted to date.

[1]  L. Makowka,et al.  Modulation of the immune response and control of tumour spread by a new synthetic compound , 1979, The British journal of surgery.

[2]  R. Kerbel,et al.  Induction of a tumor with greatly increased metastatic growth potential by injection of cells from a low‐metastatic H‐2 heterozygous tumor cell line into an H‐2 incompatible parental strain , 1978, International journal of cancer.

[3]  J. Falk,et al.  Effective antitumor immunity following elimination of suppressor T cell function. , 1978, Surgery.

[4]  D. Berd,et al.  Immunological enhancement of leukemia L1210 by Corynebacterium parvum in allogeneic mice. , 1976, Cancer research.

[5]  F. C. Sparks.  Hazards and complications of BCG immunotherapy. , 1976, The Medical clinics of North America.

[6]  S. Warner,et al.  The accumulated effects of repeated systemic or local injections of low doses of Corynebacterium parvum in mice. , 1976, Cancer research.

[7]  P. Morahan,et al.  Inhibition and enhancement of Friend leukemia virus by pyran copolymer. , 1975, Cancer research.

[8]  K. Irie,et al.  Detection of antibody and complement complexed in vivo on membranes of human cancer cells by mixed hemadsorption techniques. , 1975, Cancer research.

[9]  W. Regelson,et al.  Antitumor action of pyran copolymer and tilorone against Lewis lung carcinoma and B-16 melanoma. , 1974, Cancer research.

[10]  P. Lagrange,et al.  Immunopotentiation with BCG. I. Immune response to different strains and preparations. , 1973, Journal of the National Cancer Institute.

[11]  I. Maclennan,et al.  Some characteristics of immunoglobulin involved in antibody dependent lymphocyte cytotoxicity. , 1973, The British journal of cancer. Supplement.

[12]  J. Vaage.  Humoral and cellular immune factors in the systemic control of artifically induced metastases in C3Hf mice. , 1973, Cancer research.

[13]  I. Maclennan.  Antibody in the Induction and Inhibition of Lymphocyte Cytotoxicity , 1972, Transplantation reviews.

[14]  H. Blomgren,et al.  Specific cytotoxicity by sensitized mouse thymus cells on tissue culture target cells. , 1970, Cellular immunology.

[15]  A. Fefer.  Immunotherapy and chemotherapy of Moloney sarcoma virus-induced tumors in mice. , 1969, Cancer research.

[16]  G. Gowland,et al.  DETECTION OF HOMOGRAFT SENSITIVITY IN MICE BY THE ELIMINATION OF CHROMIUM‐51 LABELED LYMPH NODE CELLS * , 1966 .